Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: A possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation

被引:36
作者
Ruggenenti, Piero
Codreanu, Igor
Cravedi, Paolo
Perna, Annalisa
Gotti, Eliana
Remuzzi, Giuseppe
机构
[1] Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy
[2] Azienda Osped Riuniti Bergamo, Dept Med & Transplantat, Bergamo, Italy
[3] Republ Clin Hosp, Dept Haemodialysis & Kidney Transplantat, Chisnau, Moldova
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 03期
关键词
D O I
10.2215/CJN.01841105
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In high-risk kidney transplant recipients, induction therapy with rabbit anti-human thymocyte globulin (RATG) reduces the risk for acute rejection but is associated with significant toxicity, opportunistic infections, and cancer. Using reduced doses of RATG combined with anti-IL-2 antibodies may achieve the same antirejection activity of standard-dose RATG but with a better safety profile. This randomized, open-label study compared the efficacy, tolerability, and costs of low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart) versus standard-dose RATG (2 mg/kg per d) in 33 consecutive high-risk renal transplant recipients (living-related transplant recipients, sensitized patients or patients who received another transplant, and patients with delayed graft function) over 6 mo of follow-up. All patients received concomitant therapy with steroids, cyclosporin A, and azathioprine or mycophenolate mofetil. Seventeen patients received low-dose RATG plus basiliximab, and 16 received standard-dose RATG. Patient (100 versus 100%) and graft (94 versus 100%) survival were comparable in the two groups, but the incidence of fever (17.6 versus 56.5%; P = 0.01), leukopenia (23.5 versus 56.3%; P < 0.05), anemia (29.4 versus 62.5%; P < 0.05), cytomegalovirus reactivations (17.6 versus 56.5%; P = 0.01), the number of transfused units (0.5 +/- 0.9 versus 2.0 +/- 2.4; P < 0.001), and treatment costs (3652 +/- 704 versus 5400 +/- 1960 euro; P = 0.001) were lower with low-dose RATG plus basiliximab than with standard-dose RATG. There was one episode of biopsy-proven acute rejection on low-dose RATG plus basiliximab, and there were two on standard-dose RATG. In renal transplantation, induction therapy with basiliximab plus low-dose RATG effectively prevents acute rejection and is safer and more cost-effective than induction with standard-dose RATG.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 43 条
[21]  
MIGLIACCIO AR, 1987, BLOOD, V70, P1867
[22]  
MIGLIACCIO G, 1988, BLOOD, V72, P248
[23]   Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids [J].
Mourad, G ;
Rostaing, L ;
Legendre, C ;
Garrigue, V ;
Thervet, E ;
Durand, D .
TRANSPLANTATION, 2004, 78 (04) :584-590
[24]   Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens - A comparative review [J].
Nashan, B .
BIODRUGS, 2005, 19 (01) :39-46
[25]   Interleukin-10 inhibits burst-forming unit erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells [J].
Oehler, L ;
Kollars, M ;
Bohle, B ;
Berer, A ;
Reiter, E ;
Lechner, K ;
Geissler, K .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (02) :217-223
[26]   Delayed graft function: Risk factors and implications for renal allograft survival [J].
Ojo, AO ;
Wolfe, RA ;
Held, PJ ;
Port, FK ;
Schmouder, RL .
TRANSPLANTATION, 1997, 63 (07) :968-974
[27]   Lymphomas after solid organ transplantation:: A collaborative transplant study report [J].
Opelz, G ;
Döhle, B .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) :222-230
[28]   PRODUCTION OF MACROPHAGE-STIMULATING, GRANULOCYTE-STIMULATING, GRANULOCYTE-MACROPHAGE-STIMULATING AND MULTI-COLONY-STIMULATING FACTOR BY PERIPHERAL-BLOOD CELLS [J].
OSTER, W ;
LINDEMANN, A ;
MERTELSMANN, R ;
HERRMANN, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (03) :543-547
[29]   Anti-interleukin-2 receptor antibodies:: basiliximab and dactizumab [J].
Pascual, J ;
Marcén, R ;
Ortuño, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (09) :1756-1760
[30]   Delayed graft function in kidney transplantation [J].
Perico, N ;
Cattaneo, D ;
Sayegh, MH ;
Remuzzi, G .
LANCET, 2004, 364 (9447) :1814-1827